PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
Logo of advvirolJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Adv Virol. 2012; 2012: 467059.
Published online 2012 June 28. doi:  10.1155/2012/467059
PMCID: PMC3395186
Copyright © 2012 Irina Gavrilovskaya et al.
The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches
Irina Gavrilovskaya, Elena Gorbunova, Valery Matthys, Nadine Dalrymple, and Erich Mackow *
Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794-5222, USA
*Erich Mackow: erich.mackow/at/stonybrook.edu
Academic Editor: Jay Hooper
Received January 27, 2012; Revised May 16, 2012; Accepted May 18, 2012.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
American hantaviruses cause a highly lethal acute pulmonary edema termed hantavirus pulmonary syndrome (HPS). Hantaviruses nonlytically infect endothelial cells and cause dramatic changes in barrier functions of the endothelium without disrupting the endothelium. Instead hantaviruses cause changes in the function of infected endothelial cells that normally regulate fluid barrier functions of capillaries. The endothelium of arteries, veins, and lymphatic vessels is unique and central to the function of vast pulmonary capillary beds, which regulate pulmonary fluid accumulation. The endothelium maintains vascular barrier functions through a complex series of redundant receptors and signaling pathways that serve to both permit fluid and immune cell efflux into tissues and restrict tissue edema. Infection of the endothelium provides several mechanisms for hantaviruses to alter capillary permeability but also defines potential therapeutic targets for regulating acute pulmonary edema and HPS disease. Here we discuss interactions of HPS causing hantaviruses with the endothelium, potential endothelial cell-directed permeability mechanisms, and therapeutic targeting of the endothelium as a means of reducing the severity of HPS disease.
Hantaviruses predominantly infect microvascular endothelial cells (ECs), which line vessels and nonlytically cause two vascular diseases: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) [1–14]. The mechanisms by which hantaviruses cause capillary leak syndromes and disrupt fluid barrier integrity of the endothelium are beginning to be disclosed and appear to involve dysregulating EC functions that normally limit fluid leakage from the vasculature [6, 15–21].
Capillaries, veins, and lymphatic vessels are lined by a single layer of ECs which collectively form one of the largest tissues of the body [22, 23]. The endothelium forms a primary fluid barrier within vessels but serves as more than just a conduit for blood to reach and return from organs [22, 24]. The endothelium selectively restricts blood and plasma from entering tissues, regulates immune cell infiltration, and responds to damage by limiting leakage, repairing vessels, and directing angiogenesis [22]. Consequently, capillary barrier integrity is redundantly regulated by an array of EC-specific effectors that coordinately balance vascular fluid containment with tissue-specific needs and respond to a host of systemic and locally generated factors that alter inter-endothelial cell adherence junctions [22, 25–37]. ECs respond to activated platelets and immune cells, clotting cascades, chemokines and cytokines, growth factors, nitric oxide, and hypoxic conditions [22, 27, 29, 38–41]. However, ECs also secrete cytokines, complement and growth factors that positively or negatively impact the adherence and activation of platelets and immune cells, regulate responses to hypoxia, and diminish or enhance extravasation of fluid into tissues [22, 24, 26, 27, 30, 40–45]. Each of these EC responses is controlled by a diverse mesh of intertwined sensors and signals aimed at returning the endothelium to a resting state, countering permeabilizing effectors, repairing vessel damage, and restoring fluid and oxygenation levels within tissues [22, 25, 39, 41, 46–51].
The endothelium of capillaries, veins, and lymphatic vessels are unique and central to discrete functions of vast renal and pulmonary capillary beds [42, 52–54]. Nonlytic viral infection of ECs may disengage one or more fluid barrier regulatory mechanisms, thereby increasing vascular leakage or fluid clearance and as a consequence result in tissue edema [55–60]. Although the edematous accumulation of interstitial fluids can result from increased endothelial permeability, a decrease in lymphatic vessel clearance of tissue fluids is also a cause of edema and regulated by unique lymphatic endothelial cells (LECs) [42, 53, 54, 61]. Vascular permeability induced by nonlytic viruses is likely to be multifactorial in nature, resulting from virally altered EC responses, immune cell and platelet functions, hypoxia, or a collaboration of dysregulated interactions that impact normal fluid barrier function [15–18, 20, 27, 62–64]. Failure of the endothelium to regulate fluid accumulation in tissues has pathologic consequences and during HPS results in localized vascular permeability and acute pulmonary edema that contribute to cardiopulmonary insufficiency [4–6, 9]. Here we focus on the mechanisms by which HPS causing hantavirus infection of ECs induces vascular permeability and acute edema and discuss potential therapeutic mechanisms that may stabilize the endothelium.
Hantaviruses are enveloped, tripartite, negative-sense RNA viruses and form their own genus within the Bunyaviridae family [14, 65]. Hantaviruses are the only members of the Bunyaviridae that are transmitted to humans by mammalian hosts, and hantaviruses contain highly divergent RNA and protein sequences, which are likely the result of coadaptation with their hosts [13, 14, 66–68]. Single genes have been exchanged between closely related HPS causing hantaviruses [69]; however, gene reassortment has not permitted the discovery of pathogenic determinants and reverse genetics approaches have thus far proven elusive.
The hantavirus genome consists of three segments denoted S, M, and L based on the length of their RNA segments, respectively [14]. The L segment encodes the 250 kDa RNA-dependent RNA polymerase [14, 67, 70]. The S segment encodes a 48 kDa nucleocapsid (N) protein which is the most abundant hantavirus antigen present in infected cells [14, 70, 71]. The M segment encodes two viral surface glycoproteins Gn (64 kDa) and Gc (54 kDa) that are cotranslationally cleaved and targeted to the ER/cis-Golgi [14, 72]. Hantaviruses bud internally into the lumen of the cis-Golgi and exit cells via a secretory mechanism consistent with aberrant vesicular trafficking [14]. Hantaviruses are both released from ECs and remain cell associated through interactions with cell surface receptors [15, 62, 73]. GnGc heterodimers on the virion surface are presumed to bind cellular receptors and mediate viral entry into cells [14, 15, 20, 72–79].
Hantaviruses are one of only a few viruses that primarily infect the EC lining of the vasculature [8, 9, 12, 80, 81]. Hantaviruses replicate to low titers, with initial viral progeny emerging from infected ECs 18–24 hours postinfection (hpi), and ~5 × 106 maximal titers days after infection [14]. Infection of ECs is nonlytic and the permeability of infected EC monolayers is not increased by infection alone [14, 16, 82]. Prototypic HFRS (Hantaan virus-HTNV), HPS (SNV, ANDV, NY-1V) [3, 5, 10, 83, 84], and nonpathogenic (Tula virus-TULV and Prospect Hill virus-PHV) [85–87] hantaviruses all infect human ECs regardless of their ability to cause disease, suggesting that EC entry alone is not a cause of pathogenesis [12, 16, 81]. At least two requirements for hantaviruses to be pathogenic have been determined thus far, the ability of hantaviruses to regulate early interferon responses and the use of specific integrins by pathogenic (ANDV, SNV, NY-1V, PUUV, SEOV, HTNV) but not nonpathogenic (PHV, TULV) hantaviruses [20, 76, 77, 79, 88–91].
2.1. Endothelial Cell Attachment and Entry
The cellular entry of pathogenic hantaviruses is dependent on the presence of αvβ3 integrins on human ECs, while nonpathogenic hantaviruses PHV and TULV use α5β1 integrins [76, 77]. Cells expressing recombinant αvβ3 or αIIbβ3 facilitate infection by SNV, NY-1V, ANDV, and HTNV, and infection is blocked by antibodies to β3 integrins and by the β3 integrin ligand vitronectin [62, 76]. NY-1V and ANDV bind β3 integrins in an RGD-independent fashion via interactions with plexin-semaphorin-integrin (PSI) domains present at the apex of bent, inactive, αvβ3 integrin conformers [20, 79, 92–95]. Hantavirus binding to β3 maintains the integrin in a resting state and inhibits EC migration on the high-affinity αvβ3 integrin ligand vitronectin [20, 62]. Infected ECs contain cell associated hantaviruses on their surface at late times post infection [15, 62, 73]. Cell associated pathogenic hantaviruses further direct the binding of quiescent platelets to the EC surface [15]. This interaction may mask hantavirus infected cells or contribute to thrombocytopenia, which is a prominent feature of hantavirus patients. Curiously, αvβ3 integrins present on ECs normally regulate vascular permeability, and inhibiting β3 integrin functions alone causes vascular permeability disorders [41, 95–100]. Links between hantavirus dysregulation of αvβ3 functions and their role in EC permeability are discussed in detail below.
2.2. HPS Disease
At least 17 hantaviruses cause HPS, also termed hantavirus cardiopulmonary syndrome (HCPS), with prototype HPS viruses, Sin Nombre (SNV) in North America and Andes (ANDV) in South America [4–9, 101–104]. ANDV, SNV, and many closely related hantaviruses cause HPS resulting in acute pulmonary edema, cardiopulmonary insufficiency, and ~35–40% mortality rates [4–9, 13, 101–103, 105–109]. One to two weeks after infection, there is a rapid onset of pulmonary edema and hypoxia that occurs 6–12 hours after cough and rapidly progresses in severity [4–6]. Bilateral pulmonary infiltrates may be interstitial or alveolar with liters of pleural effusions observed during SNV infection [4–6, 8, 9].
Hantavirus antigen is found predominately in vast pulmonary capillary EC beds but is present in ECs within lymph nodes and throughout the body [8, 9, 80]. However, cytopathic effects are not evident following hantavirus infection of ECs in vitro or in vivo [9, 16, 82]. Histologically, the heart, kidneys, brain, and adrenals are grossly normal with pulmonary alveoli filled with acellular proteinaceous fluid, yet the alveolar epithelium remains intact [4–6, 8, 9]. The most striking HPS findings are edematous lungs with up to 8 liters of pleural edema [5, 6, 8, 9]. Pulmonary edema fluid contains few leukocytes, is largely serous in nature, and is consistent with the nearly complete loss of an alveolar capillary fluid barrier [4–6, 9]. The lack of disrupted endothelium during HPS is similar to edematous pulmonary responses observed in patients with high altitude-induced pulmonary edema [40, 60, 110–112]. The rapid onset of edematous symptoms during hantavirus infection [6] further suggests the importance of targeting vessel stability in regulating highly lethal hantavirus disease.
The endothelium lines a series of discrete vessel types that conduct fluids to and from tissues, directs the transfer of nutrients, wastes and oxygen and coordinates tissue responses to changing conditions and pathogens [22, 24, 27, 54, 59, 113–119]. Vascular ECs serve mainly as a conduit in the lining of high pressure arteries but take on a variety of fluid and cellular barrier functions in low pressure veins and capillaries that innervate organs and tissues [54]. Lymphatic vessels have a primary role in draining fluid, proteins, and immune cells from tissues and returning these components to the venous circulation [42, 52–54, 114]. Depending on their location, lymphatic vessels serve discrete fluid barrier and regulatory functions, keeping pulmonary alveolar spaces dry and clearing fluid influx from the lungs [54, 61, 120]. These diverse EC settings require discrete EC functions to effect exchange within large capillary beds of the kidney, liver, and lung [27, 54].
The EC lining is responsible for controlling vessel damage through a complex mechanism of negative regulation, rapid response and proliferation [22, 24, 40, 53, 120, 121]. Unless activated, the endothelium normally prevents immune cells and platelets from adhering to its surface [22, 122]. Endothelial quiescence is maintained by several mediators, while vascular injury activates clotting factors, platelets, and ECs resulting in the recruitment of platelets to the endothelium [22]. ECs also have angiogenic roles migrating and proliferating to fill in endothelial cell gaps or to rebuild damaged vessels [29, 123]. EC migration and vessel remodeling requires changes in cell adherence within the endothelium, and carefully orchestrated receptor signaling responses are required to accomplish this without causing edema.
The endothelial fluid barrier is primarily derived from unique adherens junctions (AJs) composed of an EC-specific vascular-endothelial cadherin (VE-cadherin) [25, 30, 45, 96, 117, 119, 124]. EC barrier functions are increased by the presence of cell surface VE-cadherin and reduced by the dissociation and internalization of VE-cadherin [25, 30, 117]. Phosphorylated VE-cadherin is internalized by its interaction with intracellular actin complexes and this process is regulated by a variety of cellular receptors and intracellular signaling pathways [25, 124, 125]. VE-cadherin phosphorylation is downregulated by an EC-specific phosphatase (VE-phosphatase) [124, 125] and several pathways that either directly or indirectly induce AJ assembly and EC integrity by returning VE-cadherin to an unphosphorylated resting state [25, 117, 125]. Chemokines, cytokines, and growth factors indirectly act on EC adherens junctions to increase vascular permeability and thus have the potential to contribute to pathogenic vascular leakage [27, 29, 96].
The endothelium contains many unique receptors that regulate AJ assembly and positively or negatively impact AJ stability and vascular integrity [33, 96, 126–129]. Vascular endothelial growth factor (VEGF) binds to EC-specific VEGFR2 receptors and activates a Src-Rac-Pak-VE-cadherin pathway resulting in AJ disassembly and vascular permeability [25, 30, 117]. Specialized ECs contain unique VEGFR1/2/3 that respond to novel forms of VEGF (VEGF A-E) and control AJ disassembly [61, 96, 130]. LECs uniquely express VEGFR3 on their surfaces and respond to VEGF-C/D but also coexpress VEGF-A responsive VEGFR2 receptors and are further regulated by the formation of VEGFR 2/3 heterodimers [39, 42, 53, 131].
VEGF was originally discovered as a potent vascular permeability factor that induces acute edema [29, 132]. VEGF reportedly acts within 0.5 mm of its release [133], and circulating soluble VEGFRs prevent VEGF from systemically permeabilizing vessels [39, 132]. VEGF is induced by hypoxia, and reduced oxygen levels at high altitudes cause high-altitude-induced pulmonary edema (HAPE) [35, 40, 113]. This results from activating the hypoxia-induced transcription factor-1α (HIF-1α), which senses oxygen levels and transcriptionally induces VEGF [59, 128, 134, 135]. VEGF further upregulates HIF-1α, forming an autocrine loop, which amplifies hypoxia-mediated VEGF responses and causes HAPE [59, 113, 136, 137]. Although this response fosters increased gas exchange, in continued low-oxygen environments these cellular responses, instead cause pulmonary edema and in HAPE, respiratory distress [40, 110, 113, 128].
As part of the normal process of vascular repair and angiogenesis, ECs migrate in response to VEGF-A stimulation in the presence of extracellular matrix [41, 95, 138]. Permeabilizing VEGFR2 responses are normally controlled by specific cell surface integrins that modulate VEGFR2 complex formation, signaling and permeability responses [96, 97, 116, 139, 140]. Ectodomains of αvβ3 and VEGFR2 form complexes that direct EC migration, a process that requires AJ disassembly, yet need to limit VEGF-A-induced permeability [96, 139]. Knocking out β3 integrins or antagonizing αvβ3 results in enhanced VEGF-A directed permeability of capillaries in vivo and in vitro [97, 141, 142]. αvβ3 antagonists are reported to promote the rapid recycling of internalized VEGFR2 to the cell surface, amplifying EC responses to VEGF [96, 97, 143].
β 3 integrin functions are further regulated by interactions with cell surface syndecan-1 and additional interactions of neuropilin-1 (Nrp-1) with VEGFR2 [127, 142, 144–147]. Nrp-1 is a VEGF-A coreceptor that forms an ectodomain complex with VEGFR2 that regulates the permeabilizing effects of VEGF [127, 142, 144, 145], and Nrp-1 binding to VEGFR2 is further regulated by the binding of semaphorin3A (sema3A) [145–147]. Endothelial roundabout receptors, Robo1 and Robo4, also impact VEGFR2-directed permeability through discrete signaling pathways [36, 48, 148–150]. Slit-2 binding to Robo1 and Robo4, respectively, have positive or negative effects on VEGF-A directed EC permeability [151, 152]. However, Robo 1/4 are differentially expressed in discrete EC beds suggesting the localized permeability effects of slit-2 [148, 152]. These findings indicate that many EC responses control capillary leakage through interconnected mechanisms and suggest that altering any number of orchestrated EC barrier functions can result in edema.
5.1. Hantavirus Binding to Inactive αvβ3 Integrins Regulates EC Functions and Permeability
Pathogenic hantaviruses bind to inactive, basal conformations of αvβ3 integrin receptors on ECs, while nonpathogenic hantaviruses interact with discrete integrins [76, 77, 79]. Receptor binding directs viral entry, but at late times postinfection cell associated hantaviruses also negatively impact αvβ3 integrin functions [15–18, 20, 62]. Days after infection, cell-associated pathogenic hantaviruses block αvβ3 integrin directed EC migration and direct the binding of quiescent platelets to the EC surface [15, 62]. Similar to antagonizing or knocking out αvβ3 integrins [96, 97], pathogenic hantavirus infection of human ECs sensitizes monolayers to the permeabilizing effects of VEGF [16, 17]. SNV-, ANDV-, and HTNV- infected ECs, but not nonpathogenic PHV or TULV infected ECs, are hyperresponsive to the permeabilizing effects of VEGF [16], and VEGFR2 is hyperphosphorylated following pathogenic hantavirus infection [15, 17, 18]. Additionally, enhanced permeability of infected ECs only occurs days after infection when cell-associated hantaviruses coat the cell surface and inactivate αvβ3 integrins [15–17, 20, 73]. These findings, in the context of hypoxic HPS patients, suggest that hantavirus binding to inactive αvβ3 integrins contributes to capillary permeability in HPS. These results further suggest a mechanism for hantavirus-enhanced EC permeability that stems from disrupting normal αvβ3-VEGFR2 interactions and enhanced VEGFR2-Src-VE-cadherin signaling responses that dissociate VE-cadherin from AJs [15–17, 20, 25, 96].
One paper suggests that ANDV-infected ECs transiently induce VEGF secretion, VE-cadherin degradation, and increased EC monolayer permeability [21]. However, several studies indicate that monolayers of hantavirus-infected ECs are not permeabilized by infection alone [16, 17, 82] and instead indicate that pathogenic hantavirus infected ECs are hyperpermeabilized by VEGF [16]. Collectively, these findings demonstrate that cell surface hantaviruses alter normal EC functions that control VEGF-directed vascular permeability [15–18, 62, 153].
5.2. Potential Role of LECs in Hantavirus Edema
Pulmonary lymphatic vessels are responsible for clearing fluid from alveoli and providing a semidry state that permits gas exchange [52, 54]. Failure of lymphatic vessels to clear fluids results in lymphedema and suggests an additional mechanism for hantavirus-infected LECs to contribute to acute pulmonary edema during HPS [42, 53, 54, 154]. Analysis of pathology samples from HPS patients indicates that hantavirus antigen is present in LECs of patient lymph nodes [8, 9, 80]. Although less is known about LECs, as described above, LECs express unique cell surface receptors and their integrity is regulated by both VEGF-A and VEGF-C [42, 53, 54, 61]. Interestingly, LEC VEGFR3 receptors respond to VEGF-C and are associated with reduced tissue edema [42, 61], while inhibiting VEGFR3 signaling results in lymphedema [42, 131]. Although a recent publication indicates that ANDV infects LECs and alters LEC barrier functions [155], the role of lymphatic vessels and LEC responses remains to be investigated in HPS patients.
5.3. Hantavirus-Endothelial Edemagenic Mechanisms
Prominent pulmonary and renal dysfunction are components of both HPS and HFRS diseases and likely stem from hantavirus infection of ECs, which line vast alveolar and renal capillary beds [4–6, 8, 9, 156, 157]. HPS patients are often young adults that arrive at hospitals in acute respiratory distress [4]. Acute pulmonary edema is a hallmark of HPS, with bilateral fluid infiltrates accumulating at up to a liter per hour resulting in pulmonary insufficiency and patient hypoxia during a critical phase of the disease [4, 6, 8, 9]. The cause of acute edema following hantavirus infection is likely to be multifactorial [6, 15–18, 64, 153, 155, 158] but revolves around the ability of the hantaviruses to infect ECs within alveolar capillary beds that normally regulate edema and gas exchange within the lung.
Clues to the mechanism of hantavirus-induced edema come from disparate findings on the role of hypoxia in acute pulmonary edema and the role of αvβ3 and VEGFR2 EC responses, which are uniquely altered by pathogenic hantaviruses [6, 15, 16, 20, 155]. Hypoxia is a prominent component of HPS patients and directs VEGF secretion from endothelial, epithelial, and immune cells [5, 6, 8, 9]. Consistent with the enhanced permeability of hantavirus-infected ECs in response to VEGF [16], HPS may be the result of hypoxia-induced VEGF that leads to acute pulmonary edema and may be exacerbated by reduced lymphatic vessel fluid clearance [155]. In fact, HPS patient VEGF levels were markedly elevated in pulmonary edema fluid and PBMCs in acute early phases of HPS [159]. Although a demonstrated role for hypoxia in hantavirus-induced permeability has yet to be conclusively defined, the ability of extracorporeal membrane oxygenation (ECMO) to reduce HPS patient mortality [4, 6] strongly suggests a role for hypoxia and VEGF in the acute pulmonary edema of HPS patients.
Only ANDV infection of Syrian hamsters (Mesocricetus auratus) serves as a model of hantavirus pathogenesis that mimics human HPS in onset symptoms and lethal acute respiratory disease [19, 160, 161]. Inoculation of Syrian hamsters with ANDV, but not SNV or other HPS causing hantaviruses, induces pathology approximating human disease. ANDV causes a fatal infection of Syrian hamsters with an LD50 of 8 plaque-forming units. The disease is characterized by large pleural effusions, congested lungs, and interstitial pneumonitis in the absence of disrupted endothelium [19, 160, 161]. The onset of pulmonary edema coincides with a rapid increase in viremia on day 6, and large inclusion bodies and vacuoles in ultrastructural studies of infected pulmonary ECs [160, 161]. Viral antigen was localized to capillary ECs, alveolar macrophages, and splenic follicular marginal zones populated by dendritic cells. Interestingly, depletion of CD4 and CD8 T-cells had no effect on the onset, course, symptoms, or outcome of ANDV infection and indicates the absence of T-cell responses [19]. Consistent with the potential involvement of β3 integrins and VEGF in this process, ANDV binds to conserved residues within PSI domains of both human and hamster β3 integrins [20, 79]. Thus the mechanism of pathogenesis caused by ANDV is consistent with hypoxia-VEGF- directed acute pulmonary edema that occurs in the absence of T-cell-mediated pathology [19]. These findings differ from a report associating T-cell responses with HPS disease, although the same data support a lack of T-cell involvement, since half of HPS patients had no elevated T-cell responses regardless of disease severity [64]. Observed T-cell responses may instead correlate with viral clearance [63, 162]. The mechanism of pathogenesis may be further elucidated by studies in Syrian hamsters and thus provides a model of ANDV pathogenesis that permits the evaluation of therapeutics that target barrier functions of the endothelium.
Currently, there are no effective therapeutics for hantavirus infections or disease. Antiviral effects of interferon or the nucleoside analog ribavirin are only effective prophylactically or at very early times postinfection [14, 163]. They appear to target early viral replication but neither is effective 1-2 weeks postinfection after the onset of HPS symptoms [4–6, 163]. An alternative approach against viruses with a long disease onset may be to therapeutically target the acute pathologic response instead of viral replication. Since hantaviruses infect and alter fluid barrier functions of the endothelium, targeting EC responses that transiently stabilize the vasculature has the potential to reduce the severity and mortality of HPS [50, 129, 164]. This approach also has the advantage of being implemented at the onset of symptoms where antiviral approaches appear to be ineffective [163].
Intracellular signaling pathways coordinately regulate the adherence of ECs to the extracellular matrix, anchor receptors to cytoskeletal elements, and induce growth factor directed migration, proliferation and permeability responses [18, 35, 41, 43, 50, 96, 116, 165, 166]. The complexity of VEGF induced permeability is further demonstrated by the reported ability of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling responses, to block VEGF-induced microvascular permeability [167–171]. This multifactorial coordination indicates why so many factors are capable of permeabilizing or stabilizing the endothelium and rationalizes their potential roles in pathogen-induced capillary leakage.
Antibody to VEGFR2 reportedly suppresses VEGF-induced pulmonary edema and suggests the potential of therapeutically antagonizing VEGFR2-Src-VE-cadherin signaling pathways as a means of reducing acute pulmonary edema during HPS [18, 25, 39, 50, 172–176]. Several well-studied VEGFR2 and Src inhibitors are in human clinical trials or are used therapeutically to treat human cancers and have the potential to reduce the severity of viral permeability-based diseases [18, 42, 50, 173, 174, 177–179]. In vitro, angiopoietin-1 (Ang-1), sphingosine-1-phosphate (S1P), pazopanib, and dasatinib inhibited EC permeability directed by pathogenic hantaviruses [16, 18]. Ang-1 is an EC-specific growth factor that transdominantly blocks VEGFR2-directed permeability in vitro and in vivo by binding to Tie-2 receptors [180–183]. S1P is a platelet derived lipid mediator, which enhances vascular barrier functions by binding to Edg-1 receptors on the endothelium [47, 172, 173, 179, 184], while pazopanib and dasatinib are drugs that inhibit VEGFR2-Src signaling [174, 185]. Pazopanib, dasatinib, and the S1P analog FTY720 are already in clinical trials or used clinically for other purposes [34, 186]. Targeting EC responses provides a potential means of stabilizing HPS patient vessels and reducing edema. The use of S1P receptor agonists has also been shown to regulate the pathogenesis of influenza virus infection by acting on ECs and reducing immune cell recruitment and entry into the lung [172]. These findings suggest the targeting of EC functions as a means of increasing capillary barrier functions and regulating immune responses that contribute to viral pathogenesis.
The regulation of additional EC receptors that stabilize interendothelial cell AJs and fluid barrier functions of the endothelium may be considered as therapeutic targets. The Robo4 receptor has been shown to inhibit VEGFR2 responses, stabilize vessels and block vascular permeability [48, 148, 152]. This new potential target is highly expressed by lung microvascular ECs and is currently being evaluated as a therapeutic for a variety of vascular disorders [149, 152]. However, Robo4 directed stability of interendothelial cell junctions may also be applicable to reducing HPS severity.
Several additional EC receptors that bind to VEGFR2 ectodomains positively or negatively regulate αvβ3-VEGFR2 functions and may provide additional therapeutic targets for regulating vascular permeability. Potential responses which need to be investigated as therapeutic targets include: NRP1, Syndecan1 (sdc1), and the insulin-like growth factor1 receptor (IGF1R), which are recruited to αvβ3 ectodomain complexes [49, 141, 142, 144, 175, 187, 188]: Surfen, a heparan sulfate containing protein that reportedly blocks EC permeability [189], and Fibulin-5, a matrix protein that reportedly promotes EC adherence by binding αvβ3 and is associated with emphysema [190–192]. However, inhibiting β3 receptors that are present on both platelets and ECs may exacerbate permeability and thus the choice of therapeutic targets is likely to be critical to increasing fluid barrier functions of the endothelium. Targeting the VEGFR2 axis that regulates EC permeability may be a central mechanism for stabilizing the endothelium and reducing the severity of HPS [127, 145, 175, 193].
These findings suggest a plethora of targets that may regulate virally induced vascular permeability and which are already clinically approved for other indications. Moreover, targeting these responses may be broadly applicable to reducing the severity of HFRS and a wide range of viral infections that impact the endothelium and cause edematous diseases.
The endothelium plays a fundamental role in vascular disease, and stabilizing the vasculature needs to be evaluated as a means for reducing the severity and mortality of viral vascular diseases. This is especially important for viral infections that cause disease 1-2 weeks after infection, at time points when antiviral approaches are no longer viable. The ability of hantaviruses to infect LECs and alter normal fluid clearance from tissues needs to be investigated and provides a unique target and mechanism for reducing edema that has yet to be considered in HPS disease. The ability of the endothelium to regulate platelet functions, complement activation, and immune responses should also be considered as central targets for reducing the severity of viral hemorrhagic and edematous diseases.
References
1. Kanerva M, Mustonen J, Vaheri A. Pathogenesis of puumala and other hantavirus infections. Reviews in Medical Virology. 1998;8(2):67–86. [PubMed]
2. Heyman P, Vaheri A, Lundkvist A, Avsic-Zupanc T. Hantavirus infections in Europe: from virus carriers to a major public-health problem. Expert Review of Anti-Infective Therapy. 2009;7(2):205–217. [PubMed]
3. Lee HW, Lee RW, Johnson KM. Isolation of the etiologic agent of Korean hemorrhagic fever. Journal of Infectious Diseases. 1978;137(3):298–308. [PubMed]
4. Chang B, Crowley M, Campen M, Koster F. Hantavirus cardiopulmonary syndrome. Seminars in Respiratory and Critical Care Medicine. 2007;28(2):193–200. [PubMed]
5. Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The New England Journal of Medicine. 1994;330(14):949–955. [PubMed]
6. Koster F, Mackow E. Pathogenesis of the hantavirus pulmonary syndrome. Future Virology. 2012;7(1):41–51.
7. Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science. 1993;262(5135):914–917. [PubMed]
8. Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Human Pathology. 1995;26(1):110–120. [PubMed]
9. Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. American Journal of Pathology. 1995;146(3):552–579. [PubMed]
10. Lähdevirta J, Enger E, Hunderi OH, Traavik T, Lee HW. Hantaan virus is related to hemorrhagic fever with renal syndrome in Norway. The Lancet. 1982;2(8298):p. 606. [PubMed]
11. Lee HW. Hemorrhagic fever with renal syndrome (HFRS). History, Hantaan virus and epidemiological features. Scandinavian Journal of Infectious Diseases. 1982;14(36):82–85. [PubMed]
12. Yanagihara R, Silverman DJ. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Archives of Virology. 1990;111(3-4):281–286. [PubMed]
13. Hjelle B, Torres-Pérez F. Hantaviruses in the Americas and their role as emerging pathogens. Viruses. 2010;2(12):2559–2586. [PMC free article] [PubMed]
14. Schmaljohn C. Bunyaviridae and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Vol. 1. Philadelphia, Pa, USA: Lipppincott-Raven; 2001. pp. 1581–1602.
15. Gavrilovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. Journal of Virology. 2010;84(9):4832–4839. [PMC free article] [PubMed]
16. Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. Journal of Virology. 2008;82(12):5797–5806. [PMC free article] [PubMed]
17. Gorbunova E, Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cell. Journal of Virology. 2010;84(14):7405–7411. [PMC free article] [PubMed]
18. Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. Journal of Virology. 2011;85(5):2296–2303. [PMC free article] [PubMed]
19. Hammerbeck CD, Hooper JW. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. Journal of Virology. 2011;85(19):9929–9944. [PMC free article] [PubMed]
20. Raymond T, Gorbunova E, Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent αvβ3 integrin conformers. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(4):1163–1168. [PubMed]
21. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. Journal of Virology. 2010;84(21):11227–11234. [PMC free article] [PubMed]
22. Aird WC. Endothelium as an organ system. Critical Care Medicine. 2004;32(5):S271–279. [PubMed]
23. Baumgartner-Parzer SM, Waldhäusl WK. The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Experimental and Clinical Endocrinology and Diabetes. 2001;109(2):S166–S179. [PubMed]
24. Valbuena G, Walker DH. The endothelium as a target for infections. Annual Review of Pathology. 2006;1:171–198. [PubMed]
25. Gavard J. Breaking the VE-cadherin bonds. FEBS Letters. 2009;583(1):1–6. [PubMed]
26. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascular Pharmacology. 2002;39(4-5):225–237. [PubMed]
27. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527–3561. [PubMed]
28. Corada M, Mariotti M, Thurston G, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(17):9815–9820. [PubMed]
29. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. 1995;146(5):1029–1039. [PubMed]
30. Gavard J, Gutkind JS. VEGF Controls endothelial-cell permeability promoting β-arrestin-dependent Endocytosis VE-cadherin. Nature Cell Biology. 2006;8(11):1223–1234. [PubMed]
31. Hippenstiel S, Krüll M, Ikemann A, Risau W, Clauss M, Suttorp N. VEGF induces hyperpermeability by a direct action on endothelial cells. American Journal of Physiology. 1998;274(5):L678–L684. [PubMed]
32. Hordijk PL. Endothelial signaling in leukocyte transmigration. Cell Biochemistry and Biophysics. 2003;38(3):305–322. [PubMed]
33. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. Journal of Cell Biology. 2006;174(4):593–604. [PMC free article] [PubMed]
34. McVerry BJ, Garcia JGN. Endothelial cell barrier regulation by sphingosine 1-phosphate. Journal of Cellular Biochemistry. 2004;92(6):1075–1085. [PubMed]
35. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375(6532):577–581. [PubMed]
36. Park KW, Morrison CM, Sorensen LK, et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Developmental Biology. 2003;261(1):251–267. [PubMed]
37. van Hinsbergh VWM, van Nieuw Amerongen GP. Endothelial hyperpermeability in vascular leakage. Vascular Pharmacology. 2002;39(4-5):171–172. [PubMed]
38. Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunology Today. 1992;13(3):106–112. [PubMed]
39. Breen EC. VEGF in biological control. Journal of Cellular Biochemistry. 2007;102(6):1358–1367. [PubMed]
40. Berger MM, Hesse C, Dehnert C, et al. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine. 2005;172(6):763–767. [PubMed]
41. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011–3025. [PubMed]
42. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology. 2010;17(4):253–261. [PubMed]
43. Brakenhielm E. Substrate matters: reciprocally stimulatory integrin and VEGF signaling in endothelial cells. Circulation Research. 2007;101(6):536–538. [PubMed]
44. Gélinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. British Journal of Pharmacology. 2002;137(7):1021–1030. [PubMed]
45. Lampugnani MG, Dejana E. The control of endothelial cell functions by adherens junctions. Novartis Foundation Symposium. 2007;283:238–241. [PubMed]
46. Kobayashi H, Lin PC. Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Frontiers in Bioscience. 2005;10:666–674. [PubMed]
47. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. Journal of Biochemistry. 2002;131(6):767–771. [PubMed]
48. Acevedo LM, Weis SM, Cheresh DA. Robo4 counteracts VEGF signaling. Nature Medicine. 2008;14(4):372–373. [PubMed]
49. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine. 2009;206(3):691–705. [PMC free article] [PubMed]
50. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia. Developmental Cell. 2008;14(1):25–36. [PubMed]
51. Lampugnani MG, Dejana E. Adherens junctions in endothelial cells regulate vessel maintenance and angiogenesis. Thrombosis Research. 2007;120(2, supplement):S1–S6. [PubMed]
52. Baluk P, Fuxe J, Hashizume H, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. Journal of Experimental Medicine. 2007;204(10):2349–2362. [PMC free article] [PubMed]
53. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends in Immunology. 2004;25(7):387–395. [PubMed]
54. Schraufnagel DE. Lung lymphatic anatomy and correlates. Pathophysiology. 2010;17(4):337–343. [PubMed]
55. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. Journal of Cell Biology. 1998;140(4):947–959. [PMC free article] [PubMed]
56. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. American Journal of Respiratory Cell and Molecular Biology. 2000;22(6):657–664. [PubMed]
57. Mutlu GM, Sznajder JI. Mechanisms of pulmonary edema clearance. American Journal of Physiology. 2005;289(5):L685–L695. [PubMed]
58. Schraufnagel DE, Agaram NP, Faruqui A, et al. Pulmonary lymphatics and edema accumulation after brief lung injury. American Journal of Physiology. 2003;284(5):L891–L897. [PubMed]
59. Dehler M, Zessin E, Bärtsch P, Mairbäurl H. Hypoxia causes permeability oedema in the constant-pressure perfused rat lung. European Respiratory Journal. 2006;27(3):600–606. [PubMed]
60. Voelkel NF. High-altitude pulmonary edema. The New England Journal of Medicine. 2002;346(21):1606–1607. [PubMed]
61. Breslin JW, Gaudreault N, Watson KD, Reynoso R, Yuan SY, Wu MH. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. American Journal of Physiology. 2007;293(1):H709–H718. [PubMed]
62. Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. Pathogenic hantaviruses selectively inhibit β3 integrin directed endothelial cell migration. Archives of Virology. 2002;147(10):1913–1931. [PubMed]
63. Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren H-G, Björkström NK. Longitudinal analysis of the human T cell response during acute hantavirus infection. Journal of Virology. 2011;85(19):10252–10260. [PMC free article] [PubMed]
64. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. Journal of Immunology. 2004;172(5):3297–3304. [PubMed]
65. Battisti AJ, Chu YK, Chipman PR, Kaufmann B, Jonsson CB, Rossmann MG. Structural studies of Hantaan virus. Journal of Virology. 2011;85(2):835–841. [PMC free article] [PubMed]
66. Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clinical Microbiology Reviews. 2010;23(2):412–441. [PMC free article] [PubMed]
67. Plyusnin A, Vapalahti O, Vaheri A. Hantaviruses: genome structure, expression and evolution. Journal of General Virology. 1996;77(11):2677–2687. [PubMed]
68. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerging Infectious Diseases. 1997;3(2):95–104. [PMC free article] [PubMed]
69. McElroy AK, Smith JM, Hooper JW, Schmaljohn CS. Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters. Virology. 2004;326(1):130–139. [PubMed]
70. Jonsson CB, Schmaljohn CS. Replication of hantaviruses. Current Topics in Microbiology and Immunology. 2000;256:15–32. [PubMed]
71. Alfadhli A, Love Z, Arvidson B, Seeds J, Willey J, Barklis E. Hantavirus nucleocapsid protein oligomerization. Journal of Virology. 2001;75(4):2019–2023. [PMC free article] [PubMed]
72. Pensiero MN, Hay J. The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently. Journal of Virology. 1992;66(4):1907–1914. [PMC free article] [PubMed]
73. Goldsmith CS, Elliott LH, Peters CJ, Zaki SR. Ultrastructural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome. Archives of Virology. 1995;140(12):2107–2122. [PubMed]
74. Schmaljohn CS, Schmaljohn AL, Dalrymple JM. Hantaan virus M RNA: coding strategy, nucleotide sequence, and gene order. Virology. 1987;157(1):31–39. [PubMed]
75. Pensiero MN, Jennings GB, Schmaljohn CS, Hay J. Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. Journal of Virology. 1988;62(3):696–702. [PMC free article] [PubMed]
76. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β3 integrins. Journal of Virology. 1999;73(5):3951–3959. [PMC free article] [PubMed]
77. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. β3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(12):7074–7079. [PubMed]
78. Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Current Topics in Microbiology and Immunology. 2000;256:91–115. [PubMed]
79. Matthys VS, Gorbunova EE, Gavrilovskaya IN, Mackow ER. Andes virus recognition of human and syrian hamster β3 integrins is determined by an L33P substitution in the PSI domain. Journal of Virology. 2010;84(1):352–360. [PMC free article] [PubMed]
80. Cosgriff TM, Lewis RM. Mechanisms of disease in hemorrhagic fever with renal syndrome. Kidney International. 1991;40(35):S72–S79. [PubMed]
81. Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. Hantaan virus infection of human endothelial cells. Journal of Virology. 1992;66(10):5929–5936. [PMC free article] [PubMed]
82. Sundstrom JB, McMullan LK, Spiropoulou CF, et al. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. Journal of Virology. 2001;75(13):6070–6085. [PMC free article] [PubMed]
83. Elliott LH, Ksiazek TG, Rollin PE, et al. Isolation of the causative agent of hantavirus pulmonary syndrome. American Journal of Tropical Medicine and Hygiene. 1994;51(1):102–108. [PubMed]
84. Schmaljohn AL, Li D, Negley DL, et al. Isolation and initial characterization of a newfound hantavirus from California. Virology. 1995;206(2):963–972. [PubMed]
85. Plyusnin A, Vapalahti O, Lankinen H, et al. Tula virus: a newly detected hantavirus carried by European common voles. Journal of Virology. 1994;68(12):7833–7839. [PMC free article] [PubMed]
86. Vapalahti O, Lundkvist A, Kukkonen SKJ, et al. Isolation and characterization of Tula virus, a distinct serotype in the genus Hantavirus, family Bunyaviridae. Journal of General Virology. 1996;77(12):3063–3067. [PubMed]
87. Lee PW, Amyx HL, Yanagihara R. Partial characterization of Prospect Hill virus isolated from voles in the United States. Journal of Infectious Diseases. 1985;152(4):826–829. [PubMed]
88. Matthys V, Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. The C-terminal 42 residues of the tula virus Gn protein regulate interferon induction. Journal of Virology. 2011;85(10):4752–4760. [PMC free article] [PubMed]
89. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(21):13837–13842. [PubMed]
90. Alff PJ, Gavrilovskaya IN, Gorbunova E, et al. The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-1- and TBK-1-directed interferon responses. Journal of Virology. 2006;80(24):p. 12430. [PMC free article] [PubMed]
91. Alff PJ, Sen N, Gorbunova E, Gavrilovskaya IN, Mackow ER. The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. Journal of Virology. 2008;82(18):9115–9122. [PMC free article] [PubMed]
92. Luo BH, Karanicolas J, Harmacek LD, Baker D, Springer TA. Rationally designed integrin β3 mutants stabilized in the high affinity conformation. Journal of Biological Chemistry. 2009;284(6):3917–3924. [PubMed]
93. Luo BH, Takagi J, Springer TA. Locking the β3 integrin I-like domain into high and low affinity conformations with disulfides. Journal of Biological Chemistry. 2004;279(11):10215–10221. [PubMed]
94. Zhu J, Luo BH, Xiao T, Zhang C, Nishida N, Springer TA. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Molecular Cell. 2008;32(6):849–861. [PMC free article] [PubMed]
95. Hynes RO. Structural biology: changing partners. Science. 2003;300(5620):755–756. [PubMed]
96. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM. β3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(11):2108–2114. [PubMed]
97. Weis SM, Cheresh DA. alphav Integrins in Angiogenesis and Cancer. Cold Spring Harbor Perspectives in Medicine. 1(1)a006478 [PMC free article] [PubMed]
98. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. Journal of Clinical Investigation. 1999;103(2):229–238. [PMC free article] [PubMed]
99. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Brazilian Journal of Medical and Biological Research. 1999;32(5):501–510. [PubMed]
100. French DL, Coller BS. Hematologically important mutations: glanzmann thrombasthenia. Blood Cells, Molecules and Diseases. 1997;23(1):39–51. [PubMed]
101. López N, Padula P, Rossi C, Lázaro ME, Franze-Fernández MT. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology. 1996;220(1):223–226. [PubMed]
102. Enria D, Padula P, Segura EL, et al. Hantavirus pulmonary syndrome in Argentina possibility of person to person transmission. Medicina. 1996;56(6):709–711. [PubMed]
103. Padula PJ, Edelstein A, Miguel SDL, López NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology. 1998;241(2):323–330. [PubMed]
104. Padula PJ, Sanchez AJ, Edelstein A, Nichol ST. Complete nucleotide sequence of the M RNA segment of Andes virus and analysis of the variability of the termini of the virus S, M and L RNA segments. Journal of General Virology. 2002;83(9):2117–2122. [PubMed]
105. Song JW, Baek LJ, Gajdusek DC, et al. Isolation of pathogenic hantavirus from white-footed mouse (Peromyscus leucopus) The Lancet. 1994;344(8937):p. 1637. [PubMed]
106. Koster F, Foucar K, Hjelle B, et al. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. American Journal of Clinical Pathology. 2001;116(5):665–672. [PubMed]
107. Levis S, Rowe JE, Morzunov S, Enria DA, St Jeor S. New hantaviruses causing hantavirus pulmonary syndrome in central Argentina. The Lancet. 1997;349(9057):998–999. [PubMed]
108. Bustamante EA, Levy H, Simpson SQ. Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest. 1997;112(4):1133–1136. [PubMed]
109. Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Critical Care Medicine. 1996;24(2):252–258. [PubMed]
110. Hanaoka M, Droma Y, Naramoto A, Honda T, Kobayashi T, Kubo K. Vascular endothelial growth factor in patients with high-altitude pulmonary edema. Journal of Applied Physiology. 2003;94(5):1836–1840. [PubMed]
111. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Molecular Medicine. 2001;7(4):240–246. [PMC free article] [PubMed]
112. Kaner RJ, Crystal RG. Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak? High Altitude Medicine and Biology. 2004;5(4):399–409. [PubMed]
113. Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology. 1998;18(6):768–776. [PubMed]
114. Breslin JW, Kurtz KM. Lymphatic endothelial cells adapt their barrier function in response to changes in shear stress. Lymphatic Research and Biology. 2009;7(4):229–237. [PMC free article] [PubMed]
115. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunology and Medical Microbiology. 2008;53(3):287–299. [PubMed]
116. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell. 2000;6(4):851–860. [PubMed]
117. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. Journal of Cell Science. 2008;121(13):2115–2122. [PubMed]
118. London NR, Whitehead KJ, Li DY. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis. 2009;12(2):149–158. [PMC free article] [PubMed]
119. Wallez Y, Vilgrain I, Huber P. Angiogenesis: the VE-cadherin switch. Trends in Cardiovascular Medicine. 2006;16(2):55–59. [PubMed]
120. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation. 2005;115(2):247–257. [PMC free article] [PubMed]
121. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling—in control of vascular function. Nature Reviews Molecular Cell Biology. 2006;7(5):359–371. [PubMed]
122. Nalbandian RM, Henry RL. Platelet endothelial cell interactions. Metabolic maps of structures and actions of prostaglandins, prostacyclin, thromboxane and cyclic AMP. Seminars in Thrombosis and Hemostasis. 1978;5(2):87–111. [PubMed]
123. Gomez D, Reich NC. Stimulation of primary human endothelial cell proliferation by IFN1. Journal of Immunology. 2003;170(11):5373–5381. [PubMed]
124. Nawroth R, Poell G, Ranft A, et al. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO Journal. 2002;21(18):4885–4895. [PubMed]
125. Broermann A, Winderlich M, Block H, et al. Dissociation of VE-PTP from ve-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. Journal of Experimental Medicine. 2011;208(12):2393–2401. [PMC free article] [PubMed]
126. Galvagni F, Pennacchini S, Salameh A, et al. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circulation Research. 2010;106(12):1839–1848. [PubMed]
127. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. Journal of Cellular Biochemistry. 2002;85(2):357–368. [PubMed]
128. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation Research. 2006;99(7):675–691. [PubMed]
129. Garcia JGN, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. Journal of Clinical Investigation. 2001;108(5):689–701. [PMC free article] [PubMed]
130. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal. 1999;13(1):9–22. [PubMed]
131. Nilsson I, Bahram F, Li X, et al. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO Journal. 2010;29(8):1377–1388. [PMC free article] [PubMed]
132. Dvorak HF. Discovery of vascular permeability factor (VPF) Experimental Cell Research. 2006;312(5):522–526. [PubMed]
133. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. Journal of Experimental Medicine. 1991;174(5):1275–1278. [PMC free article] [PubMed]
134. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling. 2007;19(10):2003–2012. [PubMed]
135. Tang N, Wang L, Esko J, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004;6(5):485–495. [PubMed]
136. Pham I, Uchida T, Planes C, et al. Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo. American Journal of Physiology. 2002;283(5):L1133–L1142. [PubMed]
137. Sidel’nikov IN, Anisimova NI. The mechanisms of the development of tissue hypoxia and the criteria for its assessment in patients with hemorrhagic fever with renal syndrome. Terapevticheskii Arkhiv. 1991;63(11):68–70. [PubMed]
138. Hutchings H, Ortega N, Plouët J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. The FASEB Journal. 2003;17(11):1520–1522. [PubMed]
139. Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. Journal of Biological Chemistry. 2000;275(51):39867–39873. [PubMed]
140. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nature Medicine. 2002;8(1):27–34. [PubMed]
141. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735–745. [PubMed]
142. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. The Journal of Biological Chemistry. 2003;278(49):48848–48860. [PubMed]
143. Hynes RO, Hodivala-Dilke KM. Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia. Thrombosis and Haemostasis. 1999;82(2):481–485. [PubMed]
144. Murga M, Fernandez-Capetillo O, Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood. 2005;105(5):1992–1999. [PubMed]
145. Becker PM, Waltenberger J, Yachechko R, et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circulation Research. 2005;96(12):1257–1265. [PubMed]
146. Gu C, Limberg BJ, Brian Whitaker G, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. Journal of Biological Chemistry. 2002;277(20):18069–18076. [PubMed]
147. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. Journal of Cell Biology. 1999;146(1):233–242. [PMC free article] [PubMed]
148. Koch AW, Mathivet T, Larrivée B, et al. Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Developmental Cell. 2011;20(1):33–46. [PubMed]
149. Marlow R, Binnewies M, Sorensen LK, et al. Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(23):10520–10525. [PubMed]
150. Weitzman M, Bayley EB, Naik UP. Robo4: a guidance receptor that regulates angiogenesis. Cell Adhesion & Migration. 2008;2(4):220–222. [PMC free article] [PubMed]
151. Fujiwara M, Ghazizadeh M, Kawanami O. Potential role of the Slit/Robo signal pathway in angiogenesis. Vascular Medicine. 2006;11(2):115–121. [PubMed]
152. Jones CA, Nishiya N, London NR, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature Cell Biology. 2009;11(11):1325–1331. [PMC free article] [PubMed]
153. Pepini T, Gorbunova EE, Gavrilovskaya IN, Mackow JE, Mackow ER. Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. Journal of Virology. 2010;84(22):11929–11936. [PMC free article] [PubMed]
154. Saharinen P, Petrova TV. Molecular regulation of lymphangiogenesis. Annals of the New York Academy of Sciences. 2004;1014:76–87. [PubMed]
155. Gavrilovskaya IN, Gorbunova EE, Mackow ER. ANDV infection oflymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and VEGF-C sensitive. Journal of Virology. In press. [PMC free article] [PubMed]
156. Lähdevirta J. Clinical features of HFRS in Scandinavia as compared with East Asia. Scandinavian Journal of Infectious Diseases. 1982;36:93–95. [PubMed]
157. Khan AS, Khabbaz RF, Armstrong LR, et al. Hantavirus pulmonary syndrome: the first 100 US cases. Journal of Infectious Diseases. 1996;173(6):1297–1303. [PubMed]
158. Krakauer T, Leduc JW, Krakauer H. Serum levels of tumor necrosis factor-α, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome. Viral Immunology. 1995;8(2):75–79. [PubMed]
159. Gavrilovskaya IN, Gorbunova EE, Koster F, Mackow ER. Elevated VEGF levelsin pulmonary edema fluid and pbmcs from patients with acute hantavirus pulmonary syndrome. In press. [PMC free article] [PubMed]
160. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology. 2001;289(1):6–14. [PubMed]
161. Wahl-Jensen V, Chapman J, Asher L, et al. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. Journal of Virology. 2007;81(14):7449–7462. [PMC free article] [PubMed]
162. Safronetz D, Zivcec M, LaCasse R, et al. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathogens. 2011;7(12)e1002426 [PMC free article] [PubMed]
163. Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Research. 2008;78(1):162–169. [PMC free article] [PubMed]
164. Jones CA, London NR, Chen H, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature Medicine. 2008;14(4):448–453. [PMC free article] [PubMed]
165. Wallez Y, Cand F, Cruzalegui F, et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene. 2007;26(7):1067–1077. [PubMed]
166. Wang Y, Jin G, Miao H, Li JYS, Usami S, Chien S. Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(6):1774–1779. [PubMed]
167. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney International. 2007;71(8):771–777. [PubMed]
168. Kim DD, Kleinman DM, Kanetaka T, et al. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation. 2010;17(2):128–136. [PMC free article] [PubMed]
169. Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Journal of Biological Chemistry. 2007;282(28):20534–20543. [PubMed]
170. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10(2):159–170. [PMC free article] [PubMed]
171. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164-Driven Angiogenesis, in Part by Blocking S6Kinase. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(8):1172–1178. [PMC free article] [PubMed]
172. Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–991. [PMC free article] [PubMed]
173. Schmid G, Guba M, Ischenko I, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. Journal of Cellular Biochemistry. 2007;101(1):259–270. [PubMed]
174. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–386. [PubMed]
175. Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008;111(5):2674–2680. [PubMed]
176. Xu D, Fuster MM, Lawrence R, Esko JD. Heparan sulfate regulates VEGF165- and VEGF121- mediated vascular hyperpermeability. Journal of Biological Chemistry. 2011;286(1):737–745. [PubMed]
177. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics. 2007;115(1):84–105. [PubMed]
178. Peng X, Hassoun PM, Sammani S, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. American Journal of Respiratory and Critical Care Medicine. 2004;169(11):1245–1251. [PubMed]
179. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphosrylation and action of the immunomodulator FTY720 inhibits ’vascular endothelial cell growth factor-induced vascular permeability. Journal of Biological Chemistry. 2003;278(47):47281–47290. [PubMed]
180. Jain RK, Munn LL. Leaky vessels? Call ang1! Nature Medicine. 2000;6(2):131–132. [PubMed]
181. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. British Journal of Pharmacology. 2003;139(2):329–336. [PubMed]
182. Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. Journal of the American Society of Nephrology. 2004;15(3):566–574. [PubMed]
183. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286(5449):2511–2514. [PubMed]
184. McVerry BJ, Garcia JGN. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cellular Signalling. 2005;17(2):131–139. [PubMed]
185. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(51):19478–19483. [PubMed]
186. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JGN. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. American Journal of Respiratory and Critical Care Medicine. 2004;170(9):987–993. [PubMed]
187. Morgan MR, Humphries MJ, Bass MD. Synergistic control of cell adhesion by integrins and syndecans. Nature Reviews Molecular Cell Biology. 2007;8(12):957–969. [PMC free article] [PubMed]
188. Beauvais DM, Rapraeger AC. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. Journal of Cell Science. 2010;123(21):3796–3807. [PubMed]
189. Schuksz M, Fuster MM, Brown JR, et al. Surfen, a small molecule antagonist of heparan sulfate. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(35):13075–13080. [PubMed]
190. Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA and Cell Biology. 2004;23(6):367–379. [PubMed]
191. Freeman LJ, Lomas A, Hodson N, et al. Accelerated publication fibulin-5 interacts with fibrillin-1 molecules and microfibrils. Biochemical Journal. 2005;388(1):1–5. [PubMed]
192. Guadall A, Orriols M, Rodríguez-Calvo R, et al. Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1α)-dependent mechanism. Journal of Biological Chemistry. 2011;286(9):7093–7103. [PubMed]
193. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells, Molecules, and Diseases. 2007;38(3):258–268. [PubMed]
Articles from Advances in Virology are provided here courtesy of
Hindawi Publishing Corporation